Sandoz' Parlodel
Executive Summary
FDA's Fertility and Maternal Health Drugs Advisory Committee will meet June 1-2 to discuss the use of Parlodel for lactation prevention. At issue is whether any potent drug should be used to suppress postpartum lactation. Sandoz submitted comments Feb. 15 to FDA in response to a citizen petition filed Nov. 29 by Health Research Group and the National Women's Health Network, which called for the deletion of lactation supression labeling from four products, including Parlodel, on the grounds that the natural resolution of lactation does not warrant the risks of reported side effects ("The Pink Sheet" Dec. 5, T&G-12).
You may also be interested in...
QUOTED. 19 April 2021. Jeff Shuren & William Maisel
Two top officials in the US FDA’s device center are warning of delays in the agency’s review of submissions for new products that aren’t directly tied to the coronavirus pandemic.
Breakthrough Therapy Designations At US FDA Stay Sluggish In 2021
With 12 new BTDs announced so far this year, 2021 is on pace to match the COVID-19-depressed total number of designations in 2020. Here’s a breakdown of the candidates that have received the designation.
Half Of US FDA’s Breakthrough Therapy Designations Have Resulted In Approval
Popular expedited review program results in a higher approval rate than the related fast track designation, but the COVID-19 era is seeing a drop in designations and a rise in complete response letters for BTD programs.